ArticleExperimental biology and medicine (Maywood, N.J.)2020
Alternative splicing of leptin receptor overlapping transcript in osteosarcoma.
Article in Experimental biology and medicine (Maywood, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- LncRNA FEZF1-AS1 regulates the gene expression and alternative splicing associated with osteosarcoma.Journal of orthopaedic surgery and research · 2025Article
- Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression.Research (Washington, D.C.) · 2025Review
- Preptin: A New Bone Metabolic Parameter?Metabolites · 2023Review
- Genome-wide identification of alternative splicing and splicing regulated in immune infiltration in osteosarcoma patients.Frontiers in genetics · 2023Article
- Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma.Frontiers in oncology · 2023Review
- The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.American journal of cancer research · 2023Article
- Innovative approaches for treatment of osteosarcoma.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma.Frontiers in cell and developmental biology · 2022Article
- Osteosarcoma subtypes based on platelet-related genes and tumor microenvironment characteristics.Frontiers in oncology · 2022Article
- Article
- Immunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma.Frontiers in veterinary science · 2021Article
- Leptin Receptor Overlapping Transcript (LEPROT) Is Associated with the Tumor Microenvironment and a Prognostic Predictor in Pan-Cancer.Frontiers in genetics · 2021Article
- A Novel Overall Survival Prediction Signature Based on Cancer Stem Cell-Related Genes in Osteosarcoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
impact statementOsteosarcoma (OS, also known as osteogenic sarcoma) is the most common primary malignancy of bone in children and adolescents. The molecular mechanisms of OS are extremely complicated and its molecular mediators remain to be elucidated. We sequenced total RNA from 18 OS bone samples (paired normal-tumor biopsies). We found statistically significant (FDR <0.05) 26 differentially expressed transcript variants of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.